Previous 10 | Next 10 |
2024-02-15 04:39:41 ET More on Prime Medicine Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing Prime Medicine stock falls on proposed public offering of common stock Prime Medicine wins up to $15M to find cure for cystic fibrosis ...
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares o...
2024-02-14 16:16:40 ET More on Prime Medicine Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing Prime Medicine wins up to $15M to find cure for cystic fibrosis Stifel cuts Prime Medicine to hold, cites quieter catalyst outlook ...
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of sh...
2024-02-12 01:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...
2024-01-28 08:11:06 ET Summary Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its...
2024-01-25 13:06:47 ET More on Prime Medicine Stifel cuts Prime Medicine to hold, cites quieter catalyst outlook Prime Medicine GAAP EPS of -$0.55 misses by $0.07 Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicin...
CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the...
2024-01-16 15:41:17 ET More on Prime Medicine Prime Medicine GAAP EPS of -$0.55 misses by $0.07 Gene editing stocks gain after Eli Lilly deal amid FDA AdCom Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicine ...
News, Short Squeeze, Breakout and More Instantly...
First Trust Heitman Global Prime Real Estate ETF Company Name:
PRME Stock Symbol:
NYSE Market:
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will partic...
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LN...